Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Assets (2016 - 2025)

Syndax Pharmaceuticals has reported Assets over the past 11 years, most recently at $529.7 million for Q4 2025.

  • Quarterly results put Assets at $529.7 million for Q4 2025, down 26.92% from a year ago — trailing twelve months through Dec 2025 was $529.7 million (down 26.92% YoY), and the annual figure for FY2025 was $529.7 million, down 26.92%.
  • Assets for Q4 2025 was $529.7 million at Syndax Pharmaceuticals, down from $551.8 million in the prior quarter.
  • Over the last five years, Assets for SNDX hit a ceiling of $724.8 million in Q4 2024 and a floor of $239.5 million in Q3 2021.
  • Median Assets over the past 5 years was $454.7 million (2021), compared with a mean of $465.5 million.
  • Biggest five-year swings in Assets: soared 165.96% in 2021 and later dropped 26.92% in 2025.
  • Syndax Pharmaceuticals' Assets stood at $449.7 million in 2021, then increased by 10.58% to $497.2 million in 2022, then grew by 23.26% to $612.9 million in 2023, then increased by 18.26% to $724.8 million in 2024, then dropped by 26.92% to $529.7 million in 2025.
  • The last three reported values for Assets were $529.7 million (Q4 2025), $551.8 million (Q3 2025), and $596.1 million (Q2 2025) per Business Quant data.